Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine
Tonix Pharmaceuticals Holding Corp. presented data on TNX-801, a live virus vaccine investigational candidate, at the World Vaccine Congress–Europe 2025.
TNX-801 is designed to provide durable protection against mpox and smallpox, demonstrating favorable safety, immunogenicity, and long-term protection in multiple preclinical models.
- Data supports the advancement of TNX-801 toward clinical development.
Titled “Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine,”
A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.
Author summary: Tonix Pharmaceuticals presents data on TNX-801 vaccine.
More News
- Unbeaten Nepal clinch ICC T20 World Cup Asia & EAP Qualifier title
- The No. 1 Chain With the Best Spaghetti and Meatballs, According to Chefs
- Meta to add parental controls for kids' interactions with AI chatbots
- The 11 Best Body-Swap Movies, Ranked | Features | Roger Ebert
- Israeli airstrikes killed 1 and injured 7 in Lebanon despite ceasefire – Ya Libnan
- Golden Knights caught in ugly fallout less than 24 Hours after Carter Hart signing
- 7 Reasons Thanos Is Marvel’s Greatest Villain
- Coinbase Asset Management & iTrustCapital partner on Bitcoin yield strategy for IRAs - CoinJournal
- Return of Mac DeMarco draws adoring crowd to Franklin Music Hall - The Triangle
- Keanu Reeves Lifts Aziz Ansari's Gentle Comedy Good Fortune